Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer. 2015

Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
Department of Breast Surgery, Jinan Central Hospital, Shandong University Jinan 250021, P.R. China.

To assess the changes in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 expression in breast cancer patients after various neoadjuvant chemotherapies. Data from 138 locally advanced breast cancer patients with histological diagnoses were reviewed. Seventy patients (group 1) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 50 mg/m(2) pirarubicin every 21 days. Sixty-eight patients (group 2) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 75 mg/m(2) docetaxel every 21 days. The biomarker changes of the operated tumor tissues were compared with the initial core biopsies. ER, PR, HER2 and Ki-67 expression changed by 28.6%, 22.9%, 17.1% and 54.3%, respectively, after neoadjuvant chemotherapy in group 1 and 16.2%, 22.1%, 13.2% and 70.6%, respectively, after neoadjuvant chemotherapy in group 2. There were significant differences between the groups regarding ER and Ki-67 status changes, and these changes can be used to inform treatment strategies.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976

Related Publications

Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
July 2022, Current oncology (Toronto, Ont.),
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
January 2022, Scientific reports,
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
January 1986, Voprosy onkologii,
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
May 2016, Journal of pathology and translational medicine,
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
June 2024, Indian journal of surgical oncology,
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
January 2009, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
July 2020, BMC cancer,
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
December 2022, Life (Basel, Switzerland),
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
November 2019, European journal of radiology,
Guangchao Jin, and Yu Han, and Cun Liu, and Liansheng Chen, and Butong Ding, and Shijin Xuan, and Xianqiang Liu, and Guohui Ma, and Jun Gao, and Xingsong Tian
March 2015, Breast cancer research : BCR,
Copied contents to your clipboard!